The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mwatha, J. K.
Right arrow Articles by Dunne, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mwatha, J. K.
Right arrow Articles by Dunne, D. W.
The Journal of Immunology, 1998, 160: 1992-1999.
Copyright © 1998 by The American Association of Immunologists

High Levels of TNF, Soluble TNF Receptors, Soluble ICAM-1, and IFN-{gamma}, but Low Levels of IL-5, Are Associated with Hepatosplenic Disease in Human Schistosomiasis Mansoni1

Joseph K. Mwatha*, Gachuhi Kimani*, Timothy Kamau*, Gabriel G. Mbugua*, John H. Ouma{dagger}, Jasper Mumo{ddagger}, Anthony J. C. Fulford§, Frances M. Jones§, Anthony E. Butterworth§, Morven B. Roberts§ and David W. Dunne2

* Kenya Medical Research Institute, {dagger} Division of Vector Borne Diseases, Kenyan Ministry of Health, and {ddagger} Department of Human Pathology, University of Nairobi, Nairobi, Kenya; and § Department of Pathology, Cambridge University, Cambridge, United Kingdom


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In a case-control study based in two areas of Kenya, hepatosplenic schistosomiasis mansoni was shown to be linked with low levels of IL-5 and with correspondingly high IFN-{gamma}, TNF, and circulating soluble TNF receptor I (sTNFR-I), sTNFR-II, and sICAM-1. PBMC from the hepatosplenic cases responded to in vitro Ag stimulation with significantly higher levels of IFN-{gamma} and TNF, but lower levels of IL-5, compared with nonhepatosplenic controls matched for age and infection intensity. Most of these correlations were confounded by differences between geographical areas. However, principle component analysis identified a high IFN-{gamma} and TNF, and low IL-5 axis in the data as the first principle component; this was significantly associated with hepatosplenomegaly (p < 0.0005) even after controlling for area. High plasma levels of sTNFR-I (p < 0.001), sTNFR-II, (p < 0.0001), and sICAM-1 (p < 0.009) were also significantly associated with hepatosplenomegaly, independently of area, in the case of the soluble forms of both TNF receptors. These parameters were negatively related to IL-5. These results suggest that proinflammatory cytokines are involved in the hepatosplenic disease process in infected individuals who have low anti-inflammatory Th2 responses and that sTNFR may be a useful circulating marker for this disease process, perhaps reflecting the level of TNF activity in hepatic tissues.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Schistosomiasis is caused by infection with parasitic trematodes of the genus Schistosoma. Adult Schistosoma mansoni worms live in the mesenteric blood vessels around the gut, and the hepatosplenic form of the disease is thought to be associated with the host’s immune response to parasite eggs lodged in the presinusoidal capillary beds of the liver (1). Most infected individuals living in schistosomiasis endemic areas do not suffer severe liver damage, but a minority go on to develop hepatosplenic morbidity characterized by hepatosplenomegaly, hepatic periportal fibrosis, and portal hypertension, which may lead to the formation of esophageal varices and hematemesis. The prevalence of hepatosplenic schistosomiasis varies significantly between different endemic areas (2, 3, 4). Although the risk of developing severe hepatosplenic disease is higher in individuals who experience higher intensities of infection (5), communities from the same tribal group in different parts of Kenya suffer markedly different prevalences of hepatosplenomegaly despite having similar intensities of infection (6), which suggests that factors other than infection intensity may influence the progression from uncomplicated infection to severe hepatosplenic disease.

Most of the available information on the immune mechanisms underlying the schistosome egg granuloma is derived from murine models and has been interpreted in terms of the Th1/Th2 paradigm, which subdivides CD4+ T cells on the basis of their characteristic patterns of cytokine production (7). The granuloma is a cell-mediated, CD4+ T cell-dependent response (8), controlled by a complex pattern of often counter-regulating cytokines, chemotactic factors, and cell adhesion factors, which successively initiate, maintain, and immunomodulate the granuloma (7). Tissue egg deposition in S. mansoni-infected mice initiates a switch of host cytokine responses from those characteristic of a Th1 or Th0 to a Th2-like pattern (9, 10, 11). Numerous experiments have demonstrated the central role of IL-4 in murine schistosomiasis granuloma formation (12, 13, 14, 15) and hepatic fibrosis (16), and the counteracting down-regulatory influence of IFN-{gamma} (15, 17, 18), which can be initiated by IL-12 (17, 18, 19). Despite the antimorbidity effects of Th1 cytokines, TNF may also be an important mediator of murine granuloma formation and hepatic fibrosis (20, 21, 22, 23); part of the influence of TNF is associated with the up-regulation of ICAM-1 expression (24).

The paucity of information on human anti-egg granulomatous responses is such that it is difficult to judge how mechanisms delineated in murine models are applicable to the human disease process. In addition to differences that may occur between the responses of any two host species to the same parasite, there are particular differences between murine models and human infections. For example: the Th1/Th2 subgrouping of human CD4+ T cells is less well defined than in the mouse; human hepatosplenic schistosomiasis develops at lower intensities of infection than it is possible to achieve on the basis of number of worms per unit of host body weight in the mouse; and human disease takes a number of years of infection to develop (25), whereas murine infections are usually studied over a few weeks or months. Relatively few studies of Ag-specific cytokine expression and human hepatosplenic schistosomiasis have been conducted. Of those that have been reported, only one (26) examined hepatosplenic patients alongside infected, nonhepatosplenic controls matched for age and intensity of infection, factors that affect immune responses in endemic populations (27). Significant associations between specific cytokine expression and human hepatosplenic disease have yet to be established (28, 29, 30). Generally, studies of inflammatory markers in sera or plasma from hepatosplenic patients have also been uncontrolled, but have shown that infection results in raised levels of TNF-{alpha} (31, 32, 33, 34), ICAM-1, and endothelial leukocyte adhesion molecule (ELAM)-1 (35). In one study that was well controlled, hepatosplenic patients had significantly raised levels of serum TNF, but their peripheral blood monocytes released less TNF when treated with mitogen (31).

In a case-control study, we examined TNF, IFN-{gamma}, and IL-5 responses of PBMC to in vitro stimulation with Con A as well as S. mansoni worm and egg Ags in groups of S. mansoni-infected patients, with and without hepatosplenomegaly, who were carefully matched for age and intensity of infection. In addition, in the same individuals, we measured plasma levels of immunologically detectable TNF-{alpha}, soluble TNF receptor I (sTNFR-I),3 sTNFR-II, and sICAM-1. The relationships between these parameters and their associations with the presence or absence of hepatosplenomegaly were analyzed.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Patients

The patients in this study came from two areas of Kenya endemic for S. mansoni, Kambu and Kangundo, described in a previous paper (6). Both are almost exclusively populated by members of the same tribe (the Kamba) and have similar mean S. mansoni infection intensities but very different rates of hepatosplenomegaly (6).

The present study followed a case-control design: 20 patients from Kambu (a high morbidity area) with hepatosplenomegaly were each matched with two controls, one from Kambu and one from Kangundo (a low morbidity area), of the same age and with similar numbers of eggs in their stools but no detectable hepatosplenomegaly.

Organomegaly was assessed by palpation by an experienced clinician (G.G.M.). Palpable livers were measured in the midsternal and midclavicular lines. Palpable spleens were measured in the midclavicular and midaxillary lines. All hepatosplenic cases had both spleen and liver enlargement of at least 2 cm, while neither organ was palpable in the controls.

Ages were matched ± 1 yr, and egg counts ± 10% as estimated from two Kato smears were prepared from a single stool. Matches could not be found for all 20 cases: 19 were matched with Kangundo controls and 17 with Kambu controls. Too few hepatosplenic cases were found in Kangundo to balance the study with respect to area. Characteristics of the patients in the study are summarized in Table IGo.


View this table:
[in this window]
[in a new window]
 
Table I. Characteristics of the patients in the study

 
Study members were admitted to the clinical research wards at the Kenya Medical Research Institute in batches of six (two sets of three matched individuals) where they were bled (20 ml venous blood) and treated with Praziquantel (40 mg/kg body weight; Bayer Ag, Leverkusen, Germany). Cellular assays were likewise performed in balanced batches of six.

Isolation and stimulation of PBMC

PBMC were isolated from heparinized blood by density gradient centrifugation on Histopaque 1077 (Sigma-Aldrich, Poole, Dorset, U.K.). PBMC were washed in RPMI 1640 (ICN Flow Biomedicals, Thame, Oxfordshire, U.K.) and resuspended at 1.5 x 106 cells/ml in Iscove’s medium (ICN Flow) supplemented with 5% AB serum (final concentration), 100 U/ml penicillin, 100 µg/ml streptomycin, and 20 mM L-glutamine. The cells were stimulated with soluble worm Ag (SWA) and soluble egg Ag (SEA) prepared from respective stages of the S. mansoni life cycle as previously described (36). Cultures of 0.75 x 106 PBMC in 0.5 ml of culture medium were stimulated with SWA and SEA at 10 µg/ml (final concentration) in a total volume of 1 ml. Con A (Sigma) was used at 1 µg/ml. The Ags and mitogen used in the study were diluted from the same batches, aliquoted, and stored at -20°C until required. Cultures were maintained at 37°C in a humidified incubator with 5% CO2 in air. Culture medium supernatants were collected after 2 days for analysis of TNF and after 4 days for IFN-{gamma} and IL-5. After collection, the supernatants were stored in aliquots at -20°C.

Cytokine and soluble receptor assays

IFN-{gamma} and IL-5 were measured as marker cytokines for, respectively, Th1- and Th2-type patterns of cytokine response. In general, cytokine assays on PBMC culture supernatants were conducted as previously described (37). The murine IL-5 dependent cell line B13 (American Type Culture Collection (ATCC), Rockville, MD) was used to determine the levels of IL-5. The fibroblastic cell line L929 (ATCC) was used to detect TNF in a rapid cytotoxicity assay. The B13 cell line was regularly checked for IL-5 dependency, while L929 was checked for TNF susceptibility. Briefly, 100 µl of B13 cells at 5 x 106 cells per ml were incubated with 100 µl of culture supernatant in 96-well tissue culture plates in a humidified incubator at 37°C in an atmosphere of 5% CO2 in air. After 3 days, cytokine-dependent cell growth was assessed using the monotetrazolium (MTT) colorimetric assay (38). To detect TNF, 100 µl of supernatant was incubated with L929 cells at 2.5 x 105 cells per ml in the presence of actinomycin D (2 µg/ml; Sigma-Aldrich) to a final volume of 200 µl in 96-well tissue culture plates. After overnight incubation, the medium was poured off and the cells were stained with 100 µl of 0.5% crystal violet in methanol. The stain was poured off, the plates were washed and then allowed to dry. One hundred microliters of 10% acetic acid was used to solublize the stain. Color release was read on a spectrophotometer at 540 nm.

To determine the levels of IFN-{gamma} in supernatants, a capture ELISA was used. Briefly, Maxisorp ELISA plates (Nunc; Life Technologies, Paisley, U.K.) were coated with mouse anti-IFN-{gamma} mAb (Interferon Sciences, New Brunswick, NJ) in carbonate/bicarbonate buffer overnight. Plates were then washed in PBS containing 0.05% Tween-20 (PBS-T) and blocked with coating buffer containing 10% FCS. Culture supernatants were added to the plates and incubated for 2 h at 37°C. IFN-{gamma} was detected by use of rabbit anti-human IFN-{gamma} at 1:800 (Department of Pathology, Cambridge University) and a goat anti-rabbit peroxidase conjugate at 1:5000 (Dako, High Wycombe, Buckinghamshire, U.K.). Finally, ABTS substrate (2, 2'-azino-bis [3-ethylbenzthiazoline 6-sulfonic acid] diammonium) was added, and the absorbance was measured at a wavelength of 405 nm. Cytokine values for each test sample were determined by interpolation from standard curves obtained with recombinant cytokines that were included in each assay plate.

Assays of the plasma concentrations of immunologically detectable TNF-{alpha}, sTNFR-I, sTNFR-II, and sICAM-1 were all conducted using commercially available sandwich ELISA assays (all from Genzyme Diagnostics, Cambridge, MA) according to the manufacturer’s instructions. Plasma samples from 10 healthy European donors, with no history of schistosomiasis, were used as uninfected plasma controls in these assays.

Statistical methods

The distributions of cytokine responses were highly skewed so that cytokine levels were categorized as either positive or negative (according to whether cytokine production of the stimulated cells was greater than the nonstimulated cells) for analysis by logistic regression.

Nonparametric tests (Kruskal-Wallis) on the raw data were used to confirm the one-way analyses. Further analysis was performed on the first principle component (MINITAB; Minitab, Inc., PA) derived from the correlation matrix of the logarithms, log(.+1), of the six in vitro Ag-stimulated PBMC cytokine production assays, TNF, IFN-{gamma}, and IL-5 production after stimulation with either SWA or SEA. The first principle component, which followed a reasonably normal distribution, was analyzed by ANOVA.

The relationship between the PBMC cytokine responses and the circulating soluble receptors/sICAM-1 was examined using Spearman’s rank correlation coefficients.

Two "contrasts" between the groups, hepatosplenic cases vs nonhepatosplenic controls and Kambu vs Kangundo, were examined. These contrasts were somewhat confounded by the lack of hepatosplenic cases from Kangundo. The carefully balanced design with respect to age and intensity of infection (fecal egg counts) eliminated any influence of these variables on the analysis; the inclusion of these variables altered none of the conclusions, and they are considered no further in this report.

The significance in terms of the logistic regression models were tested using {chi}2, the difference in deviance, which was assumed to follow a {chi}2 distribution under the null hypothesis that the term was unimportant.

Logistic regression was performed using GLIM (Numerical Algorithms Group Ltd., Oxford, U.K.), while MINITAB was used for principle component calculation, analysis of variance and Kruskal-Wallis tests. Both software packages were run on Macintosh Quadra 800 microcomputers.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In vitro cytokine production by PBMC

The results of TNF and IL-5 bioassays and IFN-{gamma} ELISA of PBMC culture supernatants after stimulation with SEA, SWA, or Con A are plotted in Figure 1Go as geometric means along with the 95% confidence intervals for each assay and each morbidity group. The results of logistic regression on morbidity group and geographical area are summarized in Table IIGo. Little difference was seen between the groups (or between morbidity or area contrasts) for any cytokine in response to Con A. Hepatosplenic cases had higher TNF and IFN-{gamma} but lower IL-5 than the controls when cells were stimulated with either SWA or SEA. These differences were significant by logistic regression (Table IIGo) in the case of TNF for both Ags, IFN-{gamma} for SWA and IL-5 for SEA. The relationship between higher levels of SWA-stimulated IFN-{gamma} remained significant even when the possible influence of different geographical areas was taken into account.



View larger version (27K):
[in this window]
[in a new window]
 
FIGURE 1. Levels of three cytokine products by PBMCs in response to stimulation with adult worm Ag (a), soluble egg Ag (b), and Con A (c) vs morbidity group.

 

View this table:
[in this window]
[in a new window]
 
Table II. Summary of logistic regression of proportion of responders vs morbidity and areaa

 
Table IIIGo shows the rank correlation coefficient for the associations between the cytokine response to each Ag/mitogen. From this comparison, it can be seen that TNF and IFN-{gamma} are positively correlated with each other, and both are negatively correlated with IL-5.


View this table:
[in this window]
[in a new window]
 
Table III. Associations between cytokine responses to SWA, SEA, and Con Aa

 
Table IVGo shows the correlation coefficients between the first principle component and the SWA- and SEA-stimulated PBMC responses (TNF, IFN-{gamma}, IL-5) from which it was derived. Since both of the IL-5 coefficients are positive, while those for the TNF and IFN-{gamma} are all negative, the first principle component appears to correspond to a spectrum of response between Th1 and Th2. The first principle component was considerably lower (i.e., more "Th1-like") among the hepatosplenic cases than the nonhepatosplenic controls (p < 0.0005 by ANOVA; Fig. 2Go), a difference that was undiminished after controlling for differences between areas.


View this table:
[in this window]
[in a new window]
 
Table IV. Correlations between the first principle component and the Ag-specific PBMC responses from which it was derived

 


View larger version (19K):
[in this window]
[in a new window]
 
FIGURE 2. First principle component of six Ag-stimulated PBMC cytokine production assays vs morbidity group.

 
Circulating inflammatory markers

Plasma from the same individuals in each morbidity group was assayed in specific TNF-{alpha} ELISA. These assays detected little or no TNF-{alpha} in any of the samples tested (data not shown). Serum levels of the sTNFR-I and -II can be better markers for tissue TNF production than serum levels of TNF itself, perhaps because of the instability or short half-life of TNF (39). Therefore, the individuals from each morbidity group were tested in ELISA to assess the levels of sTNFR-I and sTNFR-II in their plasma. These results are shown in Figure 3Go as geometric means for each soluble receptor for each group along with their 95% confidence intervals. Multiple regression analysis showed that both soluble receptors remained significantly associated with hepatosplenomegaly after controlling for differences between geographical areas (sTNFR-I: F = 15.98 on 1 and 47 df, p < 0.001; sTNFR-II: F = 31.45 on 1 and 48 df, p < 0.0001). All of the schistosome-infected groups had significantly higher levels of sTNFR compared with the uninfected European controls.



View larger version (32K):
[in this window]
[in a new window]
 
FIGURE 3. Serum levels of soluble TNF receptors vs morbidity group: a, sTNFR-I; b, sTNFR-II.

 
Levels of sICAM-1 were measured in each individual plasma by ELISA. The hepatosplenic group had higher levels of sICAM-1 (356 ng/ml ± 182) than the two matched nonhepatosplenic control groups (Kangundo: 226 ng/ml ± 110; Kambu: 250 ng/ml ± 115). The uninfected European controls had levels of circulating sICAM-1 (245 ng/ml ± 85) similar to the nonhepatosplenic, infected control groups. The difference between infected individuals with or without hepatosplenomegaly was statistically significant (F = 7.46 on 1 and 48 df, p = <0.009); however, this result just failed to reach a statistically significant level when area was allowed for in logistic regression analysis. Statistical correlations between sTNFR-I, sTNFR-II, and ICAM-1 were examined alongside the TNF, IFN-{gamma}, and IL-5 responses of PBMC to SWA, SEA, and Con A. Table VGo shows that there were statistically significant positive relationships between all three circulating soluble markers. No correlations between Con A-induced cytokines and circulating sTNFR/sICAM-1 were found (results not shown). However, the levels of all the circulating markers were found to be generally positively correlated to Ag-induced IFN-{gamma} and TNF responses (often this was statistically significant), but negatively related to IL-5 induced by the same Ags (Table VGo).


View this table:
[in this window]
[in a new window]
 
Table V. Associations between cytokine responses to SWA and SEA and to circulating sTNFR and ICAM-1a

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
High levels of TNF and IFN-{gamma}, and low levels of IL-5, produced by PBMC stimulated specifically with schistosome Ags SWA and SEA, but not with Con A, were significantly associated with the presence of hepatosplenomegaly. These are the first statistically significant relationships between Ag-specific cytokine responses and hepatosplenic schistosomiasis to be reported from a study controlled for patient age and intensity of infection. However, most of these relationships were confounded by the difference between the two areas, Kangundo and Kambu. The populations of these two areas suffer strikingly different levels of hepatosplenic disease, despite having the same ethnic background and similar intensities of infection (6). Environmental factors could influence both the prevalence of the hepatosplenic manifestation of schistosomiasis and immune responses. Such influences could be important cofactors involved in a causal linking of elevated IFN-{gamma} and TNF with disease, or merely confounding factors, having an independent effect on both cytokine profile and the occurrence of hepatosplenic involvement. We have found that the high morbidity Kambu area had a higher prevalence of malaria and that the population had a poorer nutritional status (6, 40). It is worth noting that this study was deliberately conducted outside of the malaria transmission season and that blood smears were taken from all the individuals who participated and none were found to have a detectable malaria parasitaemia. Thus, while an active malaria infection is unlikely to be a contributor to either the observed organomegaly or cytokine pattern, the possibility of a previous history of malaria having an influence cannot be eliminated by this study.

A factor that might have contributed to the Kambu nonhepatosplenic controls being less significantly different from the Kambu hepatosplenic cases than were the Kangundo controls was that, on reexamination, some Kambu controls were found to have slight hepatosplenomegaly, which was not detected in the original physical examination used to define the subjects as being hepatosplenic or nonhepatosplenic. Reexamination of the Kangundo controls did not detect any low level hepatosplenic involvement. Thus, the differences in cytokine patterns between Kambu hepatosplenics and controls found in this study could have been underestimated.

Despite these or other factors that might have added "between area differences" to any differences associated with the presence or absence of hepatosplenic disease, the use of principle components analysis clearly identified the relationship between Ag-specific IFN-{gamma} and TNF responses, on the one hand, and IL-5 responses, on the other, as being significantly associated with the presence or absence of hepatosplenomegaly, irrespective of geographical area.

Principle components analysis is a useful and commonly used technique for condensing the information contained in a set of variables. It rearranges the data into a series of new, independent variables the first of which, the first principle component, is the linear combination of the original variables, which retains the most information about the whole data set. When applied to the Ag-specific cytokine data, the coefficients of first principle component were positive for the IL-5 variables, while those for the TNF and IFN-{gamma} variables were all negative, i.e., the analysis identified a broad "Th1-Th2 axis" as the most prominent feature of the observed cytokine profiles. Subsequent ANOVA on this first principle component revealed that those with hepatosplenic disease gave a significantly more "Th1-like" response than those from either of the two control groups.

The identification of a broad cytokine axis associating IFN-{gamma} and TNF (which for convenience we have called "Th1-like") on the one hand and IL-5 on the other is not surprising. Although TNF can be produced by a number of different types of cells, TNF-{alpha} is mainly produced by activated macrophages (41). TNF is generally associated with Th1-like responses, since Th1 cells can produce TNF directly and, by producing IFN-{gamma}, they enhance the production of TNF through its macrophage-activating function (42). In addition, a number of Th2 cytokines have been shown to limit the expression and activity of Th1 cells. IL-4 is known to cause a reduction in the production of TNF, possibly by regulating TNF gene expression (43).

Accumulated evidence from many studies, using a variety of mouse models, strongly supports the hypothesis that Th2-type cytokine responses, and IL-4 in particular, are critical in promoting the schistosome egg granuloma. It has been shown that in vivo neutralization of IL-4 suppresses egg granuloma formation, while administration of rIL-4 enhances the granuloma response and decreases Th1-like cytokine responses, including IFN-{gamma} (12, 13, 14, 15). Anti-IL-4 treatment also significantly suppresses hepatic collagen formation and expression of IL-5 and IL-13 mRNA in the liver (16). Neutralization of endogenous IFN-{gamma} has been shown usually to decrease murine granuloma size (13, 15, 17, 44), while granuloma formation occurs normally in IFN-{gamma} knockout mice (18). Thus the observations reported here, that in vitro stimulation with SEA and SWA induce PBMC from patients with hepatosplenomegaly to produce more IFN-{gamma} and less IL-5 than nonhepatosplenic controls, would not be predicted from the well-established association between Th2 cytokine responses, egg granuloma formation, hepatic fibrosis, and portal hypertension seen in the mouse. However, the significantly higher levels of Ag-induced TNF in hepatosplenic patients can be more easily related to a number of murine schistosomiasis studies. Anti-TNF serum reduced, and treatment with TNF-{alpha} increased, hepatic granuloma size in S. mansoni-infected mice (20). Similarly, rTNF-{alpha} has been shown to reconstitute granuloma formation in S. mansoni-infected SCID mice (21), and worm-induced TNF-{alpha} has been shown to mediate the immune priming necessary for hepatic granuloma formation after injection of S. mansoni eggs into naive mice (23).

A particularly interesting S. mansoni-mouse model has been described by Henderson and colleagues (45). In this model, CBA/J mice chronically infected (10 to 20 wk in the mouse) with S. mansoni, develop two distinct syndromes designated moderate splenomegaly syndrome (MSS) and hypersplenomegaly syndrome (HSS), which are similar to, respectively, the nonhepatosplenic (also termed "intestinal") and hepatosplenic forms of schistosomiasis seen in human populations. HSS occurs in about 20% of infected mice and is a strikingly more severe form of the infection, characterized by massive splenomegaly, ascites, thymic atrophy, severe anemia, and cachexia. In addition, HSS mice suffer increased perioval and hepatic periportal fibrosis (45). Recently, it has been shown that CBA/J mice that go on to develop HSS fail to modulate the production of TNF-{alpha} mRNA in their livers and suffer greater liver fibrosis than MSS mice (22). Interestingly, IL-4 knockout mice also suffer severe TNF-{alpha}-mediated morbidity when infected with S. mansoni (46). As TNF-{alpha} is associated with the induction and maintenance of fibrotic reactions (47, 48, 49), and as large amounts are produced by IFN-{gamma} activated macrophages (41), it is possible that chronically elevated levels of IFN-{gamma} and TNF (and low levels of counter-regulating Th2 cytokines) might predispose some schistosome-infected individuals to the development of hepatic fibrosis and hepatosplenic disease.

Some previous human studies have pointed toward the involvement of TNF in hepatosplenic schistosomiasis. In a well-controlled study, Zwingenberger and colleagues (31) found higher TNF levels in serum of patients with hepatosplenic disease compared with patients without organomegaly. Similar observations were made on Egyptian schistosomiasis patients who were not controlled for age and intensity of infection (33, 34). In addition, TNF secreted by nonstimulated monocytes and serum TNF was found to be elevated in S. haematobium-infected patients with carcinoma of the urinary bladder (32).

Our failure to detect significant levels of plasma TNF-{alpha} may have been because the methods used to separate PBMC for in vitro studies were not optimal for the preservation of plasma TNF. However, in a variety of infectious diseases, it has been shown that circulating levels of TNF are increased only transiently in the early stages of infection, while circulating concentrations of sTNFR remain elevated for longer periods (39). Circulating levels of sTNFR-I or sTNFR-II have been found to be more useful than circulating TNF for monitoring the course of disease or morbidity in a variety of infections such as, for example, leishmaniasis (50), tuberculosis (51), HIV infections, (52) and rickettsiosis (53). In addition, circulating levels of sTNFR were found to be useful indicators of disease activity and prognosis for cancer (54) and rheumatoid arthritis (55). Here, we have found that elevated plasma levels of sTNFR-I and sTNFR-II are strongly and significantly correlated with the presence of hepatosplenic disease. These correlations are significant, irrespective of geographical area, and are supportive of the observation that elevated Ag-specific release of TNF is a characteristic feature of the hepatosplenic form of human schistosomiasis.

In experimental animal models, the administration of sTNFR can neutralize the pathologic effects of TNF (56). TNFR:Fc has been shown to neutralize the biologic activity of TNF-{alpha} in mice (57) and in human transplantation patients (58), and it reduces granuloma size in murine schistosomiasis (24). It might have been expected, therefore, that high levels of sTNFR would be negatively associated with hepatosplenic disease, rather than the positive relationship found in this study. However, it also appears that sTNFR can stabilize TNF-{alpha} and may facilitate its biologic activity (59). The positive correlations shown in this study (Table VGo) between circulating sTNFR and in vitro TNF production by Ag-stimulated PBMC, in particular the statistically significant correlation between the TNF response to SEA and circulating sTNFR-I, suggest that sTNFR may be directly related to up-regulated TNF and, therefore, may be acting as a circulating marker for the local production of TNF in host tissues. It is interesting to note that Josimovic-Alasevic and colleagues observed that elevated concentrations of soluble 55 kDa IL-2R subunit are detectable in the sera of hepatosplenic schistosomiasis patients (60).

In addition to proinflammatory cytokines and their antagonists, intercellular adhesion molecules may be important in the murine anti-egg granulomatous response. Elevated ICAM-1 expression is associated with murine acute phase granuloma formation (61). Anti-ICAM-1 Ab treatment suppresses murine S. mansoni egg granuloma formation, and injection of sTNFR:Fc down-regulates both granuloma formation and ICAM-1 expression (24). Secor and colleagues (35) have found that the circulating, soluble form of ICAM-1 was significantly higher in hepatosplenic Brazilian patients than in nonhepatosplenic infected individuals but, unfortunately, because of the age-distribution of infection intensity and morbidity in the study population, they were unable to directly match their subjects for age and intensity of infection. Our results support those of Secor and colleagues, in that circulating levels of sICAM-1 were significantly higher in Kenyan hepatosplenic patients than in the matched nonhepatosplenic controls, although this relationship fell just below the level of statistical significance when geographical area was taken into account.

In the present study, there was a consistent pattern of positive, often statistically significant, correlations between Ag-induced TNF and IFN-{gamma} and circulating sTNFR-I/-II and sICAM-1; and there were negative associations between these parameters and IL-5 (Table VGo). This pattern, together with the relationship between these response patterns and hepatosplenomegaly, strongly suggests a link, perhaps causal, between Th1 responses to schistosome Ags, up-regulated proinflammatory cytokines, and adhesion molecules, and the development of hepatosplenic schistosomiasis.

A particular strength of this study design is that age and intensity of infection, which are important influences on immunologic responses in schistosome-infected populations, have been fully controlled for, thereby greatly increasing the chances of the identification of any immune correlations of hepatosplenic disease. However, the corollary is that the influence of these factors on morbidity cannot be assessed in this study, and therefore, caution should be exercized in extrapolating these results to the relationship between immunologic responses and hepatosplenic disease in older, perhaps less heavily infected individuals. Similarly, the current study groups were selected on the basis of hepatosplenomegaly rather than ultrasonography-detectable hepatic fibrosis, and it is important to acknowledge that the detailed relationship between these two aspects of schistosomiasis-associated morbidity remains largely undefined. We are, therefore, currently undertaking cross-sectional population studies, in addition to further case-control studies, to evaluate the relationship between immune responses, hepatosplenomegaly, and hepatic fibrosis. Cross-sectional studies of schistosomiasis endemic populations will complement the case-control study design, as no preselection of study subjects is involved, and therefore, the influences on both age and intensity of infection can be examined by multiple regression analysis.

The immune correlates of schistosomiasis-associated hepatosplenic disease reported in this study appear to contrast with the established role of Th2 responses in murine granuloma formation and hepatosplenic morbidity. The S. mansoni egg is a powerful stimulus to Th2-type cytokine responses. However, in evolutionary terms, it would be unfortunate if the predominant response of the natural host (man) to a common parasite was an entirely immunopathologic one. Indeed, most schistosome-infected individuals in endemic regions do not develop severe hepatosplenic disease. This being so, it is possible that a dominant Th2-like response to the egg may actually represent a normal, relatively nonpathologic, anti-inflammatory response in human schistosomiasis. In that case, it would be the minority of infected individuals, with a poor Th2 response, who fail to regulate their proinflammatory responses and consequently risk suffering severe hepatosplenic disease. While this conclusion is necessarily speculative, it does underline the need for further, carefully controlled studies of the interactions between human immune responses and schistosomiasis-induced hepatosplenic disease.


    Acknowledgments
 
The authors thank the Director of the Kenyan Medical Research Institute for permission to publish this paper and the people of Kangundo and Kambu for their participation in this study.


    Footnotes
 
1 This work received financial support from the British Medical Research Council, the Wellcome Trust, the Commission of the European Communities-STD3, and the World Health Organization/Special Programme for Research and Training in Tropical Diseases. Back

2 Address correspondence and reprint requests to David W. Dunne, Division of Microbiology and Parasitology, Department of Pathology, Cambridge University, Tennis Court Road, Cambridge, CB2 IQP, U.K. E-mail address: Back

3 Abbreviations used in this paper: sTNFR-I, soluble TNF receptor I; SWA, S. mansoni soluble worm Ag; SEA, S. mansoni soluble egg Ag; ANOVA, analysis of variance; MSS, moderate splenomegaly syndrome; HSS, hypersplenomegaly syndrome. Back

Received for publication August 26, 1997. Accepted for publication October 23, 1997.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Boros, D. L.. 1994. The role of cytokines in formation of the schistosome egg granuloma. Immunobiology 191:441.[Medline]
  2. Doehring-Schwerdtfeger, E., I. M. Abdel-Rahim, Q. Mohamed-Ali, M. Elsheikh, J. Schlake, R. Kardorff, D. Franke, C. Kaiser, J. H. H. Ehrich. 1990. Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: evaluation of morbidity. Am. J. Trop. Med. Hyg. 42:581.
  3. Gryseels, B., A. M. Polderman. 1987. The morbidity of schistosomiasis mansoni in Maniema (Zaire). Trans. R. Soc. Trop. Med. Hyg. 81:202.[Medline]
  4. Kardorff, R., M. Traore, A. Diarra, M. Sacko, M. Maiga, D. Franke, U. Vester, U. Hansen, H. A. Traore, S. Fongoro, H. Gorgen, R. Korte, B. Gryseels, E. Doehring-Schwerdtfeger, J. H. H. Ehrich. 1994. Lack of ultrasonographic evidence for severe hepatosplenic morbidity in schistosomiasis mansoni in Mali. Am. J. Trop. Med. Hyg. 51:190.
  5. Siongok, T. K. A., A. A. F. Mahmoud, J. H. Ouma, K. S. Warren, A. K. Muller, A. K. Hander, H. B. Houser. 1976. Morbidity in schistosomiasis mansoni in relation to intensity of infection: study of a community in Kisumu, Kenya. Am. J. Trop. Med. Hyg. 25:273.
  6. Fulford, A. J. C., G. G. Mbugua, J. H. Ouma, H. C. Kariuki, R. F. Sturrock, A. E. Butterworth. 1991. Differences in the rate of hepatosplenomegaly due to Schistosoma mansoni infection between two areas in Machakos district, Kenya. Trans. R. Soc. Trop. Med. Hyg. 85:481.[Medline]
  7. Wynn, T. A., A. W. Cheever. 1995. Cytokine regulation of granuloma formation in schistosomiasis. Curr. Opin. Immunol. 7:505.[Medline]
  8. Mathew, R. C., D. L. Boros. 1986. Anti-L3T4 antibody treatment suppresses hepatic granuloma formation and abrogates antigen-induced interleukin 2 production in Schistosoma mansoni infection. Infect. Immun. 54:820.[Abstract/Free Full Text]
  9. Grzych, J. M., E. J. Pearce, A. Cheever, Z. A. Caulada, P. Caspar, S. Heiny, F. Lewis, A. Sher. 1991. Egg deposition is the major stimulus for the production of Th2 cytokines in murine schistosomiasis mansoni. J. Immunol. 147:3921.[Abstract]
  10. Pearce, E. J., P. Casper, J. M. Grzych, F. A. Lewis, A. Sher. 1991. Downregulation of TH1 cytokine production accompanies induction of TH2 responses by a helminth, Schistosoma mansoni. J. Exp. Med. 173:159.[Abstract/Free Full Text]
  11. Vella, A. T., E. J. Pearce. 1992. CD4+ Th2 response induced by Schistosoma mansoni eggs develops rapidly, through an early, transient, Th0-like stage. J. Immunol. 148:2283.[Abstract]
  12. Yamashita, T., D. L. Boros. 1992. IL-4 influences IL-2 production and granulomatous inflammation in murine schistosomiasis mansoni. J. Immunol. 149:1430.
  13. Chensue, S. W., P. D. Terebuh, K. S. Warmington, S. D. Hershey, H. L. Evanoff, S. L. Kunkel, G. I. Higashi. 1992. Role of interleukin-4 and gamma-interferon in Schistosoma mansoni egg-induced hypersensitivity granuloma formation: orchestration, relative contribution, and relationship to macrophage function. J. Immunol. 148:900.[Abstract]
  14. Wynn, T. A., I. Eltoum, A. W. Cheever, F. A. Lewis, W. C. Guase, A. Sher. 1993. Analysis of cytokine mRNA expression during primary granuloma formation induced by eggs of Schistosoma mansoni. J. Immunol. 151:1430.[Abstract]
  15. Lukacs, N. W., D. L. Boros. 1993. Lymphokine regulation of granuloma formation in murine schistosomiasis mansoni. J. Immunol. 68:57.
  16. Cheever, A. W., M. E. Williams, T. A. Wynn, F. D. Finkelman, R. A. Seder, T. M. Cox, S. Hieny, P. Casper, A. Sher. 1994. Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis. J. Immunol. 153:753.[Abstract]
  17. Wynn, T. A., I. Eltoum, I. P. Oswald, A. W. Cheever, A. Sher. 1994. Endogenous interleukin 12 (IL12) regulates granuloma formation induced by eggs of Schistosoma mansoni and exogenous IL12 both inhibits and prophylactically immunises against egg pathology. J. Exp. Med. 179:1551.[Abstract/Free Full Text]
  18. Wynn, T. A., D. Jankovic, S. Hieny, K. Zioncheck, P. Jardieu, A. W. Cheever, A. Sher. 1995. IL-12 exacerbates rather than suppresses T helper 2-dependent pathology in the absence of endogenous IFN-{gamma}. J. Immunol. 154:3999.[Abstract]
  19. Wynn, T. A., A. W. Cheever, D. Jankovic, R. W. Poindexter, P. Casper, F. A. Lewis, A. Sher. 1995. An IL12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 376:594.[Medline]
  20. Joseph, A. L., D. L. Boros. 1993. Tumour necrosis factor plays a role in Schistosoma mansoni egg-induced granulomatous inflammation. J. Immunol. 151:5461.[Abstract]
  21. Amiri, P., R. M. Locksley, D. G. Parslow, M. Sadick, E. Rector, D. Ritter, J. H. McKerrow. 1992. Tumour necrosis factor restores granulomas and induces parasite egg laying in schistosome infected SCID mice. Nature 356:604.[Medline]
  22. Adewusi, O. I., N. A. Nix, X. Lu, D. G. Colley, W. E. Secor. 1996. Schistosoma mansoni: relationship of tumor necrosis factor-{alpha} to morbidity and collagen deposition in chronic experimental infection. Exp. Parasitol. 84:115.[Medline]
  23. Leptak, C. L., J. H. McKerrow. 1997. Schistosomiasis egg granuloma and hepatic expression of TNF-{alpha} are dependent on immune priming during parasite maturation. J. Immunol. 158:301.[Abstract]
  24. Lukacs, N. W., S. W. Chensue, R. M. Strieter, K. Warmington, S. L. Kunkel. 1994. Inflammatory granuloma formation is mediated by TNF-alpha-inducible intercellular adhesion molecule-1. J. Immunol. 152:5883.[Abstract]
  25. Wiest, P. M.. 1996. The epidemiology of morbidity of schistosomiasis. Parasitol. Today 12:215.[Medline]
  26. Zwingenberger, K., E. Irschick, J. G. Siqueira Vergetti, A. R. Correia Dacal, R. Janssen-Rosseck, U. Bienzle, C. Huber, H. Feldmeier. 1989. Release of interleukin-2 and gamma interferon by peripheral mononuclear cells in human Schistosoma mansoni infection normalizes after chemotherapy. Scand. J. Immunol. 30:463.[Medline]
  27. Butterworth, A. E., E. L. Corbett, D. W. Dunne, A. J. C. Fulford, G. Kimani, R. K. Klump, G. Mbugua, J. H. Ouma, T. K. Siongok, R. F. Sturrock. 1989. Immunity and morbidity in human schistosomiasis mansoni. K. P. W. J. McAdam, ed. New Strategies in Parasitology 193. Churchill Livingstone, Edinburgh.
  28. Bahia-Oliveira, L. M. G., G. Gazzinelli, S. M. Eloi-Santos, J. R. Cunha-Melo, L. F. Alves-Oliveira, A. M. S. Silveira, I. R. C. Viana, J. Carmo, A. Souza, R. Correa-Oliveira. 1992. Differential cellular reactivity to adult worm antigens of patients with different clinical forms of schistosomiasis mansoni. Trans. R. Soc. Trop. Med. Hyg. 86:57.[Medline]
  29. Bahia-Oliveira, L. M. G., A. J. G. Simpson, L. F. Alves-Oliveira, C. Carvalho-Queiroz, A. M. S. Silveira, I. R. C. Viana, J. R. Cunha-Melo, P. Hagan, G. Gazzinelli, R. Correa-Oliveira. 1996. Evidence that cellular immune responses to soluble and membrane associated antigens are independently regulated during human schistosomiasis mansoni. Parasite Immunol. 18:53.[Medline]
  30. Williams, M. E., S. Montenegro, A. L. Domingues, T. A. Wynn, K. Teixeira, S. Mahanty, A. Coutinho, A. Sher. 1994. Leukocytes of patients with Schistosoma mansoni respond with a TH2 pattern of cytokine production to mitogen or egg antigens but with a Th0 pattern to worm antigens. J. Infect. Dis. 170:946.[Medline]
  31. Zwingenberger, K., E. Irschick, J. G. Vergetti Siqueira, A. R. Correia Dacal, H. Feldmeier. 1990. Tumour necrosis factor in hepatosplenic schistosomiasis. Scand. J. Immunol. 31:205.[Medline]
  32. Raziuddin, S., M. Masihuzzaman, S. Shetty, A. Ibrahim. 1993. Tumor necrosis factor alpha production in schistosomiasis with carcinoma of urinary bladder. J. Clin. Immunol. 13:23.[Medline]
  33. Azim, A. A., H. A. Sedky, M. A. El-Tahawy, A. A. Fikry, H. Mostafa. 1995. Serum levels of tumor necrosis factor in different stages of schistosomal infection. J. Egypt. Soc. Parasitol. 25:279.[Medline]
  34. Khalil, H. M., A. G. El-Missiry, H. M. F. Abdalla, N. M. Khalil, N. M. Sabry, H. E. Abdel-Atty, F. A. Tamara, M. El-Tayeb, N. M. Zakaria. 1995. Serum levels of tumour necrosis factor-alpha in schistosomiasis mansoni and their analogous changes in collagen diseases and schistosomal arthropathy. J. Egypt. Soc. Parasitol. 25:427.[Medline]
  35. Secor, W. E., G. R. Mittermayer, E. A. G. Ramos, E. P. Matos, E. A. G. Reis, T. M. A. Carmo, D. A. Harn. 1994. Soluble intercellular adhesion molecules in human schistosomiasis: correlations with disease severity and decreased responsiveness to egg antigens. Infect. Immun. 63:2695.
  36. Dunne, D. W., A. E. Butterworth, A. J. C. Fulford, H. C. Kariuki, J. G. Langley, J. H. Ouma, A. Capron, R. J. Pierce, R. F. Sturrock. 1992. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur. J. Immunol. 22:1483.[Medline]
  37. Roberts, M., A. E. Butterworth, K. Gachuhi, T. Kamau, A. J. C. Fulford, D. W. Dunne, J. H. Ouma, R. F. Sturrock. 1993. Immunity after treatment of human schistosomiasis: association between cellular responses and resistance to re-infection. Infect. Immun. 61:4984.[Abstract/Free Full Text]
  38. Mossman, T. R.. 1991. Cytokine secretion patterns and cross-regulation of T cell subsets. regulation of immune responses by T cells with different cytokine secretion phenotypes: role of a new cytokine, cytokine synthesis inhibitory factor (IL10). Immunol. Res. 10:183.[Medline]
  39. Van Deuren, M.. 1994. Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections. Eur. J. Clin. Microbiol. Infect. Dis. 13:S12.
  40. Corbett, E. L., A. E. Butterworth, A. J. C. Fulford, J. H. Ouma, R. F. Sturrock. 1992. Nutritional status of children with schistosomiasis mansoni in two different areas of Machakos district, Kenya. Trans. R. Soc. Trop. Med. Hyg. 86:266.[Medline]
  41. Vassalli, P.. 1992. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:411.[Medline]
  42. Farrar, M. A., R. D. Schreiber. 1993. The molecular cell biology of interferon-gamma and its receptor. Annu. Rev. Immunol. 11:571.[Medline]
  43. Essner, R., K. Rhoades, W. H. McBride, D. L. Morton, J. S. Economou. 1989. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J. Immunol. 142:3857.[Abstract]
  44. Chensue, S. W., K. S. Warmington, J. H. Ruth, P. Lincoln, S. L. Kunkel. 1995. Cytokine function during mycobacterial and schistosomal antigen-induced granuloma formation: local and regional participation of IFN-gamma, IL-10 and TNF. J. Immunol. 154:5969.[Abstract]
  45. Henderson, G. S., N. A. Nix, M. A. Montesano, D. Gold, G. L. Freeman, T. L. McCurley, D. G. Colley. 1993. Two distinct pathological syndromes in male CBA/J inbred mice with chronic Schistosoma mansoni. Am. J. Pathol. 142:703.[Abstract]
  46. Rosa Brunet, L., F. D. Finkelman, A. W. Cheever, M. A. Kopf, E. J. Pearce. 1997. IL-4 projects against TNF-{alpha} mediated cachexia and death during acute schistosomiasis. J. Immunol. 159:777.[Abstract]
  47. Piguet, P. F., M. A. Collart, G. E. Grau, A. P. Sappino, P. Vassalli. 1990. Requirement of tumor necrosis factor for development of silica-induced pulmonary fibrosis. Nature 344:245.[Medline]
  48. Miyazaki, Y., K. Araki, C. Vesin, I. Garcia, Y. Kapanci, J. A. Whitsett, P. F. Piguet, P. Vassalli. 1995. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis: a mouse model of progressive pulmonary fibrosis. J. Clin. Invest. 96:250.
  49. Piguet, P. F., S. Kaufman, C. Barazzone, M. Muller, B. Ryffel, H. P. Eugster. 1997. Resistance of TNF/LT alpha double deficient mice to bleomycin-induced fibrosis. Int. J. Exp. Path. 78:43.[Medline]
  50. Zijlstra, E. E., T. Van der Poll, M. Mevissen. 1995. Soluble receptors for tumor necrosis factor as markers of disease activity in visceral leishmaniasis. J. Infect. Dis. 171:498.[Medline]
  51. Kawaguchi. H., Y., S. Ina, S. Ito, Y. Sato, H. Sugiura, N. Tomita, K. Ogisu, M. Takada, M. Yamamoto, M. Morishita, K. Yoshikawa. 1996. Serum levels of soluble tumor necrosis factor (TNF) receptors in patients with pulmonary tuberculosis. Kekkaku 71:259.[Medline]
  52. Godfried, M. H., J. A. Romijn, T. Van der Poll, G. J. Weverling, E. P. M. Corssmit, E. Endert, J. K. E. Schattenkerk, H. P. Sauerwein. 1995. Soluble receptors for tumor necrosis factor are markers for clinical course but not for major metabolic changes in human immunodeficiency virus infection. Metabol. Clin. Exp. 44:1564.
  53. Kern, W, J. V, F. Oristrell, F. Segura Porta, P. Kern. 1996. Release of soluble tumor necrosis factor receptors in Mediterranean spotted fever rickettsiosis. Clin. Diagn. Lab. Immunol. 3:233.[Abstract]
  54. Gadducci, A., M. Ferdeghini, C. Castellani, C. Annicchiarico, O. Gagetti, C. Prontera, R. Bianchi, V. Facchini. 1995. Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer. Gynecol. Oncol. 58:184.[Medline]
  55. Barrera, P., C. J. Haagsma, A. M. Th. Boerbooms, P. L. C. M. Van Riel, G. F. Borm, L. B. A. Van De Putte, J. W. M. Van Der Meer. 1995. Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists: longitudinal evaluation in patients with rheumatoid arthritis. Br. J. Rheumatol. 34:747.[Abstract/Free Full Text]
  56. Ulich, T. R., E. S. Yi, S. Yin, C. Smith, D. Remick. 1994. Intratracheal administration of endotoxin and cytokines. VII. The soluble interleukin-1 receptor and the soluble tumor necrosis factor receptor II (p80) inhibit acute inflammation. Clin. Immunol. Immunopathol. 72:137.[Medline]
  57. Laichalk, L. L., S. L. Kunkel, R. M. Strieter, J. M. Danforth, M. B. Bailie, T. J. Standiford. 1996. Tumor necrosis factor mediates lung antibacterial host defence in murine Klebsiella pneumonia. Infect. Immun. 64:5211.[Abstract]
  58. Wee, S., M. Pascual, J. D. Eason, D. A. Schoenfeld, J. Phelan, S. Boskovic, C. Blosch, K. Mohler, A. B. Cosimi. 1997. Biological effects and fate of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy 1. Transplantation 63:570.[Medline]
  59. Aderka, D., H. Engelmann, Y. Maor, C. Brakebusch, D. Wallach. 1992. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 175:323.[Abstract/Free Full Text]
  60. Josimovic-Alasevic, O., H. Feldmeier, K. Zwingenberger, G. Harms, H. Hahn, T. Diamantstein. 1988. IL2-receptor in systemic parasitic disease. Clin. Exp. Immunol. 72:249.[Medline]
  61. Ritter, D. M., J. H. McKerrow. 1996. Intercellular adhesion molecule 1 is the major adhesion molecule expressed during schistosome granuloma formation. Infect. Immun. 64:4706.[Abstract]



This article has been cited by other articles:


Home page
J. Immunol.Home page
P. M. Smith, M. G. Shainheit, L. E. Bazzone, L. I. Rutitzky, A. Poltorak, and M. J. Stadecker
Genetic Control of Severe Egg-Induced Immunopathology and IL-17 Production in Murine Schistosomiasis
J. Immunol., September 1, 2009; 183(5): 3317 - 3323.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
L. E. Bazzone, P. M. Smith, L. I. Rutitzky, M. G. Shainheit, J. F. Urban, T. Setiawan, A. M. Blum, J. V. Weinstock, and M. J. Stadecker
Coinfection with the Intestinal Nematode Heligmosomoides polygyrus Markedly Reduces Hepatic Egg-Induced Immunopathology and Proinflammatory Cytokines in Mouse Models of Severe Schistosomiasis
Infect. Immun., November 1, 2008; 76(11): 5164 - 5172.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
S. Wilson, F. M. Jones, J. K. Mwatha, G. Kimani, M. Booth, H. C. Kariuki, B. J. Vennervald, J. H. Ouma, E. Muchiri, and D. W. Dunne
Hepatosplenomegaly Is Associated with Low Regulatory and Th2 Responses to Schistosome Antigens in Childhood Schistosomiasis and Malaria Coinfection
Infect. Immun., May 1, 2008; 76(5): 2212 - 2218.
[Abstract] [Full Text] [PDF]


Home page
Am J Trop Med HygHome page
N. BERHE, B. L. HALVORSEN, T. E. GUNDERSEN, B. MYRVANG, S. G. GUNDERSEN, and R. BLOMHOFF
REDUCED SERUM CONCENTRATIONS OF RETINOL AND {alpha}-TOCOPHEROL AND HIGH CONCENTRATIONS OF HYDROPEROXIDES ARE ASSOCIATED WITH COMMUNITY LEVELS OF S. MANSONI INFECTION AND SCHISTOSOMAL PERIPORTAL FIBROSIS IN ETHIOPIAN SCHOOL CHILDREN
Am J Trop Med Hyg, May 1, 2007; 76(5): 943 - 949.
[Abstract] [Full Text] [PDF]


Home page
Am J Trop Med HygHome page
H. M. COUTINHO, T. LEENSTRA, L. P. ACOSTA, L. SU, B. JARILLA, M. A. JIZ, G. C. LANGDON, R. M. OLVEDA, S. T. MCGARVEY, J. D. KURTIS, et al.
PRO-INFLAMMATORY CYTOKINES AND C-REACTIVE PROTEIN ARE ASSOCIATED WITH UNDERNUTRITION IN THE CONTEXT OF SCHISTOSOMA JAPONICUM INFECTION.
Am J Trop Med Hyg, October 1, 2006; 75(4): 720 - 726.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
L. F. Alves Oliveira, E. C. Moreno, G. Gazzinelli, O. A. Martins-Filho, A. M. S. Silveira, A. Gazzinelli, L. C. C. Malaquias, P. LoVerde, P. M. Leite, and R. Correa-Oliveira
Cytokine Production Associated with Periportal Fibrosis during Chronic Schistosomiasis Mansoni in Humans
Infect. Immun., February 1, 2006; 74(2): 1215 - 1221.
[Abstract] [Full Text] [PDF]


Home page
Am J Trop Med HygHome page
A. E. EZEAMAMA, J. F. FRIEDMAN, L. P. ACOSTA, D. C. BELLINGER, G. C. LANGDON, D. L. MANALO, R. M. OLVEDA, J. D. KURTIS, and S. T. MCGARVEY
HELMINTH INFECTION AND COGNITIVE IMPAIRMENT AMONG FILIPINO CHILDREN
Am J Trop Med Hyg, May 1, 2005; 72(5): 540 - 548.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. I. Rutitzky, H. J. Hernandez, Y.-S. Yim, D. E. Ricklan, E. Finger, C. Mohan, I. Peter, E. K. Wakeland, and M. J. Stadecker
Enhanced Egg-Induced Immunopathology Correlates With High IFN-{gamma} in Murine Schistosomiasis: Identification of Two Epistatic Genetic Intervals
J. Immunol., January 1, 2005; 174(1): 435 - 440.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
A. Ribeiro de Jesus, A. Magalhaes, D. Gonzalez Miranda, R. Gonzalez Miranda, M. I. Araujo, A. Almeida de Jesus, A. Silva, L. B. Santana, E. Pearce, and E. M. Carvalho
Association of Type 2 Cytokines with Hepatic Fibrosis in Human Schistosoma mansoni Infection
Infect. Immun., June 1, 2004; 72(6): 3391 - 3397.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
S. Joseph, F. M. Jones, G. Kimani, J. K. Mwatha, T. Kamau, F. Kazibwe, J. Kemijumbi, N. B. Kabatereine, M. Booth, H. C. Kariuki, et al.
Cytokine Production in Whole Blood Cultures from a Fishing Community in an Area of High Endemicity for Schistosoma mansoni in Uganda: the Differential Effect of Parasite Worm and Egg Antigens
Infect. Immun., February 1, 2004; 72(2): 728 - 734.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Booth, J. K. Mwatha, S. Joseph, F. M. Jones, H. Kadzo, E. Ireri, F. Kazibwe, J. Kemijumbi, C. Kariuki, G. Kimani, et al.
Periportal Fibrosis in Human Schistosoma mansoni Infection Is Associated with Low IL-10, Low IFN-{gamma}, High TNF-{alpha}, or Low RANTES, Depending on Age and Gender
J. Immunol., January 15, 2004; 172(2): 1295 - 1303.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
C. Eboumbou Moukoko, N. El Wali, O. K. Saeed, Q. Mohamed-Ali, J. Gaudart, A. J. Dessein, and C. Chevillard
No Evidence for a Major Effect of Tumor Necrosis Factor Alpha Gene Polymorphisms in Periportal Fibrosis Caused by Schistosoma mansoni Infection
Infect. Immun., October 1, 2003; 71(10): 5456 - 5460.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. C. La Flamme, A. S. MacDonald, C. R. Huxtable, M. Carroll, and E. J. Pearce
Lack of C3 Affects Th2 Response Development and the Sequelae of Chemotherapy in Schistosomiasis
J. Immunol., January 1, 2003; 170(1): 470 - 476.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Henri, C. Chevillard, A. Mergani, P. Paris, J. Gaudart, C. Camilla, H. Dessein, F. Montero, N.-E. M. A. Elwali, O. K. Saeed, et al.
Cytokine Regulation of Periportal Fibrosis in Humans Infected with Schistosoma mansoni: IFN-{gamma} Is Associated with Protection Against Fibrosis and TNF-{alpha} with Aggravation of Disease
J. Immunol., July 15, 2002; 169(2): 929 - 936.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
A. S. MacDonald, M. I. Araujo, and E. J. Pearce
Immunology of Parasitic Helminth Infections
Infect. Immun., February 1, 2002; 70(2): 427 - 433.
[Full Text] [PDF]


Home page
Infect. Immun.Home page
A. C. La Flamme, E. A. Patton, and E. J. Pearce
Role of Gamma Interferon in the Pathogenesis of Severe Schistosomiasis in Interleukin-4-Deficient Mice
Infect. Immun., December 1, 2001; 69(12): 7445 - 7452.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. I. Rutitzky, H. J. Hernandez, and M. J. Stadecker
Th1-polarizing immunization with egg antigens correlates with severe exacerbation of immunopathology and death in schistosome infection
PNAS, October 16, 2001; (2001) 231258498.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
M. I. Araujo, S. K. Bliss, Y. Suzuki, A. Alcaraz, E. Y. Denkers, and E. J. Pearce
Interleukin-12 Promotes Pathologic Liver Changes and Death in Mice Coinfected with Schistosoma mansoni and Toxoplasma gondii
Infect. Immun., March 1, 2001; 69(3): 1454 - 1462.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. C. La Flamme, E. A. Patton, B. Bauman, and E. J. Pearce
IL-4 Plays a Crucial Role in Regulating Oxidative Damage in the Liver During Schistosomiasis
J. Immunol., February 1, 2001; 166(3): 1903 - 1911.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. F. Hoffmann, A. W. Cheever, and T. A. Wynn
IL-10 and the Dangers of Immune Polarization: Excessive Type 1 and Type 2 Cytokine Responses Induce Distinct Forms of Lethal Immunopathology in Murine Schistosomiasis
J. Immunol., June 15, 2000; 164(12): 6406 - 6416.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
H. Asahi, A. Osman, R. M. Cook, P. T. LoVerde, and M. J. Stadecker
Schistosoma mansoni Phosphoenolpyruvate Carboxykinase, a Novel Egg Antigen: Immunological Properties of the Recombinant Protein and Identification of a T-Cell Epitope
Infect. Immun., June 1, 2000; 68(6): 3385 - 3393.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
P. W. Mola, I. O. Farah, T. M. Kariuki, M. Nyindo, R. E. Blanton, and C. L. King
Cytokine Control of the Granulomatous Response in Schistosoma mansoni-Infected Baboons: Role of Exposure and Treatment
Infect. Immun., December 1, 1999; 67(12): 6565 - 6571.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
C. Cetre, C. Pierrot, C. Cocude, S. Lafitte, A. Capron, M. Capron, and J. Khalife
Profiles of Th1 and Th2 Cytokines after Primary and Secondary Infection by Schistosoma mansoni in the Semipermissive Rat Host
Infect. Immun., June 1, 1999; 67(6): 2713 - 2719.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. I. Rutitzky, H. J. Hernandez, and M. J. Stadecker
Th1-polarizing immunization with egg antigens correlates with severe exacerbation of immunopathology and death in schistosome infection
PNAS, November 6, 2001; 98(23): 13243 - 13248.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mwatha, J. K.
Right arrow Articles by Dunne, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mwatha, J. K.
Right arrow Articles by Dunne, D. W.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS